Table 3.
Comparison of pre-treatment T-cell subsets between cancer-free male controls and LTS or STS
| T-cell subsetsa | Groupsb | Medianc (Ranged) | p-valuee | |||
|---|---|---|---|---|---|---|
|
| ||||||
| PD-1+ CD4 T eff cells | Cancer-free controls | 11.7 (6.67 – 14.30) |
|
|||
| LTS week 0 | 10.1 (5.4 – 14.5) | |||||
| STS week 0 | 22.2 (8.4 – 33.0) | |||||
|
| ||||||
| PD-1+ CD8 T cells | Cancer-free controls | 13.7 (8.7 – 27.5) |
|
|||
| LTS week 0 | 15.0 (5.31 – 28.0) | |||||
| STS week 0 | 22.2 (8.4 – 33.0) | |||||
a
T-cell subsets are defined by immune markers as indicated in the table;
b
cancer-free male controls, n = 7; LTS, n = 8; STS, n = 12;
c
Median values of PD-1 positive cells are % of the respective parent gate;
d
Values in brackets () are range of each data set;
e
Mann-Whitney test;
Bold-faced characters highlight p-value ≤ 0.017 (Bonferroni correction); LTS, long-term survivors; STS, short-term survivors